ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL - Episode 4
Shifting Treatment Paradigms in R/R ALL
Panelists discuss how minimal residual disease (MRD) outcomes with obecabtagene autoleucel (obe-cel) compare with those with brexucabtagene autoleucel (brexu-cel) and how the FDA approval of obe-cel may impact treatment decisions in relapsed/refractory acute lymphoblastic leukemia (R/R ALL), including considerations for patient factors, such as MRD status, Philadelphia status, and high-risk features.
Video content above is prompted by the following:
- Dr. O’Dwyer to Dr. Shaughnessy: What are your impressions of the MRD outcomes with obe-cel compared with MRD outcomes reported with brexu-cel so far?
- Resource links: Valtis YK et al. MRD negativity D28 after brexu-cel. ASH 2024 abstract, or see Appendix 5.
- Dr. O’Dwyer to Dr. Logan [then open to panelists]: How does the FDA approval of obe-cel change your treatment landscape and decisions for R/R ALL?
- Are there specific patients with R/R ALL for whom you would more likely consider brexu-cel vs obe-cel [eg, Philadelphia status, MRD status, high-risk features, extramedullary disease, age, performance score]?
- Does the FDA approval without a Risk Evaluation Mitigation Strategy program influence your treatment approach?